Want to see CH:NOVN full AI Analyst Report?
NOVN Analyst Ratings
Moderate Buy
6 Buy
7 Hold
1 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
NOVN Stock 12 Month Forecast
Average Price Target
CHF129.38
▲(1.96% Upside)
| Highest Price TargetCHF142.00 | Average Price TargetCHF129.38 | Lowest Price TargetCHF110.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
UBS
CHF116
Hold
-8.59%
Downside
Reiterated
07/22/26
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
UBS
CHF116
Hold
-8.59%
Downside
Reiterated
07/22/26
Best Analysts Covering Novartis AG
3 Months
Success Rate
23/31 ratings generated profit
Average Return
+4.13%
Copying David Evans's trades and holding each position for 3 Months would result in 74.19% of your transactions generating a profit, with an average return of +4.13% per trade.
1 Year
Success Rate
31/31 ratings generated profit
Average Return
+15.62%
Copying David Evans's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +15.62% per trade.
2 Years
Success Rate
31/31 ratings generated profit
Average Return
+30.07%
Copying David Evans's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +30.07% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
NOVN Analyst Recommendation Trends
Rating
Mar 26
Apr 26
May 26
Jun 26
Jul 26
Strong Buy
0
0
0
0
0
Buy
22
24
22
20
20
Hold
14
15
11
12
14
Sell
6
6
5
2
2
Strong Sell
0
0
0
0
0
total
42
45
38
34
36
Each month's total comprises the sum of three months' worth of ratings.
NOVN Financial Forecast
NOVN Stock Forecast FAQ
What is CH:NOVN’s average 12-month price target, according to analysts?
Based on analyst ratings, Novartis AG’s 12-month average price target is 129.38.
What is CH:NOVN’s upside potential, based on the analysts’ average price target?
Novartis AG has 1.96% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Novartis AG a Buy, Sell or Hold?
Novartis AG has a consensus rating of Moderate Buy, which is based on 6 buy ratings, 7 hold ratings and 1 sell ratings.
What is Novartis AG’s share price target?
The average share price target for Novartis AG is 129.38. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is CHF142.00 ,and the lowest forecast is CHF110.00. The average share price target represents 1.96% Increase from the current price of CHF126.9.
The highest analyst share price target is CHF142.00 ,and the lowest forecast is CHF110.00. The average share price target represents 1.96% Increase from the current price of CHF126.9.
What do analysts say about Novartis AG?
Novartis AG’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 14 Wall Streets Analysts.
How can I buy shares of Novartis AG?
To buy shares of CH:NOVN, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.








